Topline Six-Month Results From Phase IIb Study of Avicursen
Filed with ASX · · 3 pages · English
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Clinical Trial Update
- Results of Share Purchase Plan
- Percheron to launch Share Purchase Plan
- $13.0 million Institutional Placement
- Completion of avicursen (ATL1102) toxicology study
Later from Percheron Therapeutics
- Letter From The Chair and Half Year Accounts
- Response to ASX Query
- Trading Halt
- Percheron licenses HMBD-002 from Hummingbird Bioscience
- Appendix 4E and Annual Report
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics